[{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"81d99580-964a-4d43-9dfd-629d1f93a58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642626","created_at":"2021-01-18T17:52:54.288Z","updated_at":"2024-07-02T16:35:14.310Z","phase":"","brief_title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","source_id_and_acronym":"NCT03642626","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-18"},{"id":"0915db70-1d7a-4b71-89fc-c57ba5cd500e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993949","created_at":"2023-08-15T19:10:31.904Z","updated_at":"2024-07-02T16:35:20.287Z","phase":"Phase 1","brief_title":"Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05993949","lead_sponsor":"Stanford University","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-02-08"},{"id":"f19e108a-124d-4401-9821-80498de86393","acronym":"ZUMA-3","url":"https://clinicaltrials.gov/study/NCT02614066","created_at":"2021-01-18T12:41:58.535Z","updated_at":"2024-07-02T16:35:28.969Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)","source_id_and_acronym":"NCT02614066 - ZUMA-3","lead_sponsor":"Kite, A Gilead Company","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2023-11-16"},{"id":"f93aa5c3-cc4a-45e1-8ddf-a3a1ce20cd04","acronym":"ZUMA-18","url":"https://clinicaltrials.gov/study/NCT04162756","created_at":"2021-01-18T20:18:03.282Z","updated_at":"2024-07-02T16:36:23.048Z","phase":"","brief_title":"Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies","source_id_and_acronym":"NCT04162756 - ZUMA-18","lead_sponsor":"Kite, A Gilead Company","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel) • cyclophosphamide intravenous"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-10-14"}]